New hope for kids with tough cancers: experimental drug combo trial opens
NCT ID NCT05004116
Summary
This study is testing whether a new drug called repotrectinib, when given with standard chemotherapy, is safe and effective for children and young adults (up to age 30) whose solid tumors have come back or stopped responding to other treatments. Researchers will first find the safest dose and then see if the combination helps control the cancer. The trial is for patients with various advanced solid tumors, including some brain tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.